Key Takeaways DGX's Haystack Oncology partners with Rutgers Cancer Institute on a lung cancer research trial.Quest Diagnostics offers Haystack MRD as a CLIA-validated, lab-developed test.DGX is well-placed in the expanding MRD market, driven by cancer trends and new technologies.Quest Diagnostics (DGX) company, Haystack Oncology, recently announced a research collaboration with the Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center. The partners will ...